)
Overview
<ul>
<li>Canada cannabis firm’s fiscal Q1 net revenue rose 49% yr/yr but missed analyst expectations</li>
<li>Adjusted EBITDA for fiscal Q1 increased significantly, driven by higher recreational and international revenue</li>
<li>Company achieved genetic screening breakthrough for powdery mildew resistance, improving yield stability</li>
</ul>
Outlook
<ul>
<li>Organigram expects continued growth in international sales throughout Fiscal 2026</li>
<li>Company is preparing for EU-GMP certification for its Moncton facility</li>
</ul>
Result Drivers
<ul>
<li>MOTIF ACQUISITION - Net revenue growth driven by contributions from Motif Labs acquisition and increased international sales</li>
<li>GROSS MARGIN IMPROVEMENT - Adjusted gross margin rose due to operational efficiencies, higher flower yields, and Motif integration synergies</li>
<li>GENETIC BREAKTHROUGH - Achieved genetic screening breakthrough for powdery mildew resistance, enhancing yield stability and reducing costs</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q1 Miss C$63.54 C$73.15
Revenue mln mln (5
Analysts
)
Q1 Gross C$97.30
Revenue mln
Q1 Net C$19.97
Income mln
<h3>Q1 C$5.27</h3>
Adjusted mln
<h3>EBITDA</h3>
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 4 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the healthcare facilities &amp; services peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Organigram Global Inc is C$3.25, about 49.8% above its February 9 closing price of C$2.17</li>
</ul>
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Canadian cannabis firm Organigram's Q1 net revenue jumps 49%